Form 8-K

8-K — Rafael Holdings, Inc.

Accession: 0001213900-26-076411

Filed: 2026-07-08

Period: 2026-07-08

CIK: 0001713863

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0297442-8k_rafael.htm (Primary)

EX-99.1 — INVESTOR PRESENTATION (ea029744201ex99-1.htm)

GRAPHIC (ea029744201_ex99-1img1.jpg)

GRAPHIC (ea029744201_ex99-1img2.jpg)

GRAPHIC (ea029744201_ex99-1img3.jpg)

GRAPHIC (ea029744201_ex99-1img4.jpg)

GRAPHIC (ea029744201_ex99-1img5.jpg)

GRAPHIC (ea029744201_ex99-1img6.jpg)

GRAPHIC (ea029744201_ex99-1img7.jpg)

GRAPHIC (ea029744201_ex99-1img8.jpg)

GRAPHIC (ea029744201_ex99-1img9.jpg)

GRAPHIC (ea029744201_ex99-1img10.jpg)

GRAPHIC (ea029744201_ex99-1img11.jpg)

GRAPHIC (ea029744201_ex99-1img12.jpg)

GRAPHIC (ea029744201_ex99-1img13.jpg)

GRAPHIC (ea029744201_ex99-1img14.jpg)

GRAPHIC (ea029744201_ex99-1img15.jpg)

GRAPHIC (ea029744201_ex99-1img16.jpg)

GRAPHIC (ea029744201_ex99-1img17.jpg)

GRAPHIC (ea029744201_ex99-1img18.jpg)

GRAPHIC (ea029744201_ex99-1img19.jpg)

GRAPHIC (ea029744201_ex99-1img20.jpg)

GRAPHIC (ea029744201_ex99-1img21.jpg)

GRAPHIC (ea029744201_ex99-1img22.jpg)

GRAPHIC (ea029744201_ex99-1img23.jpg)

GRAPHIC (ea029744201_ex99-1img24.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0297442-8k_rafael.htm · Sequence: 1

false

0001713863

2026-07-08

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): July 8, 2026

RAFAEL

HOLDINGS, INC.

(Exact

name of registrant as specified in its charter)

Delaware

1-38411

82-2296593

(State

or other jurisdiction

Incorporation)

(Commission File

Number)

(IRS

Employer

Identification

No.)

520

Broad Street

Newark,

New Jersey

07102

(Address

of principal executive offices)

(Zip Code)

Registrant’s

telephone number, including area code: 212 658-1450

Not

Applicable

(Former

name or former address, if changed since last report.)

Check the

appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any

of the following provisions (see General Instruction A.2. below):

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material

pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities

registered pursuant to Section 12(b)-2 of the Exchange Act:

Title

of each class

Trading

Symbol

Name

of each exchange on which registered

Class

B common stock, par value $0.01 per share

RFL

New

York Stock Exchange

Item 7.01.

Regulation FD

From

July 8, 2026, the slide presentation (the “Presentation”) attached hereto as Exhibit 99.1 will be available on the Registrant’s

website at the following link: https://rafaelholdings.irpass.com/.

The

Registrant is furnishing the information contained in this Report, including Exhibit 99.1, pursuant to Item 7.01 of Form 8-K promulgated

by the Securities and Exchange Commission (the “SEC”). This information shall not be deemed to be “filed” with

the SEC or incorporated by reference into any other filing with the SEC. In addition, the Presentation contains statements intended as

“forward-looking statements” that are subject to the cautionary statements about forward-looking statements set forth in

the Presentation.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.

Document

99.1

Investor Presentation

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to

the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the

undersigned hereunto duly authorized.

RAFAEL

HOLDINGS, INC.

By:

/s/

David Polinsky

Name:

David Polinsky

Title:

Chief

Financial Officer

Dated:

July 8, 2026

EXHIBIT

INDEX

Exhibit

Number

Document

99.1

Investor Presentation

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

EX-99.1 — INVESTOR PRESENTATION

EX-99.1

Filename: ea029744201ex99-1.htm · Sequence: 2

Exhibit 99.1

NYSE: RFL July 2026 | Investor Presentation

Forward-Looking Statements Some of the information in this presentation relates to future events or future business and financial performance. Such statements constitute forward-looking information within the meaning of the Private Securities Litigation Act of 1995. Such statements can be only predictions and the actual events or results may differ from those discussed due to, among other things, the risks described in the public filings and other publications of Rafael Holdings, Inc. Forward-looking statements are identified by words such as "anticipates", "projects", "expects", "plans", "intends", "believes", "estimates", "target", and other similar expressions that indicate trends and future events. The market data and certain other statistical information used throughout this presentation are based on independent industry publications, governmental publications, reports by market research firms or other independent sources. Some data are also based on the Company's good faith estimates. In addition, this presentation includes summaries of scientific activities and outcomes that have been condensed to aid the reader in gaining general understanding. The information about Rafael Holdings, Inc. and its subsidiaries is solely for information purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state. Factors that could cause the Company's results to differ materially from those expressed in forward looking statements include, without limitation, the Company's need for additional capital; the Company's reliance on its Trappsol® Cyclo product, which may never receive regulatory approval; the Company's ability to commercialize any of its proposed drug products if it receives regulatory approval; the outcome of the Company's clinical trials, which may not support the Company's product claims or may result in adverse side effects; the cost and timing of the Company's clinical trials; the Company's reliance on third parties to conduct clinical trials and to produce its products; other risks associated with being a clinical stage biotechnology company; a small number of the Company's customers account for a substantial portion of our revenue, and the loss of any of these customers would materially decrease our revenues; and the Company may be negatively affected by currency exchange rate fluctuations. This presentation is not to be copied, transmitted, displayed, distributed (for compensation or otherwise), or altered in any way without the prior written consent of Rafael Holdings, Inc. 2

Clinical Drug Development Trappsol® Cyclo 3 Focused on Bringing Trappsol® Cyclo to Market Real Estate Holding Medical Devices Rafael Holdings, Inc. NYSE: RFL / NYSE American: RFLW

Investment Highlights 4 Experienced team with strong track record of success Lead program Trappsol ® Cyclo in Phase 3 trial for the treatment of Niemann-Pick Disease Type C1 High unmet medical need in NPC; global market expected to reach >$920m by 2031 Independent unblinded Data Monitoring Committee (DMC) performed Interim analysis in June 2025 and recommended continuation of the study through final analysis at 96-weeks. Strong balance sheet with sufficient capital to fund through multiple potentially value creating milestones Late clinical-stage biotechnology company dedicated to developing life- changing medicines through science and innovation for patients and families living with challenging diseases Completed LPLV June 2026; Pre-NDA meeting completed; NDA submission and Topline data expected 2nd half 2026

5 Leadership Team Howard S. Jonas Chairman of the Board Karen Mullen, FFPM Chief Medical Officer David Polinsky Chief Financial Officer Joshua Fine Chief Operating Officer

6 Trappsol® Cyclo Is Being Evaluated in the Fully Enrolled TransportNPC Phase 3 Clinical Trial for Patients With Niemann-Pick Disease Type C1 48-week interim analysis (IA) from Phase 3 Trial completed June 13 Data monitoring committee recommended continuing study to the 96-week final analysis Potential to be a market leading treatment in newborn patients and above treating both systemic and neurological manifestations of NPC Orphan Drug Designation in US and EU, Fast Track in US, Rare Pediatric Disease Designated in US allowing for Priority Review Voucher eligibility Completed LPLV June 2026; Pre-NDA meeting completed; NDA submission and Topline data expected 2nd half 2026

Niemann-Pick Disease Type C1 Ongoing Pivotal Phase 3 Study 7

Niemann Pick Type C1 (NPC) Market Overview 8 Incidences 1/100,000 ~35/year in U.S. ~3% are age 3 and below Diagnosed Patients ~97% age 3 and up ~60% age 16 and up Median Survival Early infantile (2m-2): 4.6y Late infantile (3-6): 9.4y Juvenile (7-15): 15.4y Adult (16+): 12.2y Existing Cases >9,000 in 80 countries ~900 in U.S. • NPC can manifest at any age and is characterized by progressive organ failure and neurodegeneration • Recent studies estimate the prevalence of NPC in the US is approximately 2.9 cases per million, which translates to around 943 cases • Many of which are likely untreated due to challenges around diagnosis and rarity of the disease • Late onset of symptoms can lead to longer life spans, but it is extremely rare for any person with NPC to reach age 40 Sources: Battisti et al, 2003; Schicks et al, 2013; Sévin et al, 2007; Trendelenburg et al, 2006; Vanier et al, 2010), Burton BK, Ellis AG, Orr B, et al. Estimating the prevalence of Niemann-Pick disease (NPC) in the United States. Mol Genet Metab. 2021; (134) doi: 10.1016/j.ymgme.2021.06.011, Data commissioned by Tessellon Inc, for Cyclo Therapeutics, LLC.; Neimann Pick Foundation NPC is a rare, fatal, autosomal recessive lysosomal storage disease that disrupts lipid trafficking within cells, leading to the toxic buildup of unesterified cholesterol and glycosphingolipids in major organs. Overview

Trappsol® Cyclo Differentiated MOA 9 NPC1, a key regulator in late endosomal/lysosomal compartments, regulates cholesterol efflux Biallelic NPC1 mutations trap cholesterol in lysosomes, block autophagy and drive cell death Trappsol® Cyclo facilitates cholesterol release independent of NPC1/NPC2, bypassing transport blockades and offering significant potential benefits for NPC patients Uniquely Enables the Effective Transport of Cholesterol Out of Cells Baseline 14 Weeks Baseline 14 Weeks Baseline 14 Weeks Cholesterol as measured by Filipin staining at Baseline and after 7 doses over 14 weeks (3 Patients) 1500 Mg/kg (Mild) Reduction 2500 Mg/kg (Marked) Reduction 2500 Mg/kg (Marked) Reduction

10 Trappsol® Cyclo Summary of Completed Studies and Open-Label Extension Trappsol® Cyclo reaches the cerebrospinal fluid within hours of IV infusion, modulating cholesterol metabolism and clearing cellular cholesterol, mirroring preclinical NPC model effects Study 1011 Study 102 Demonstrated Trappsol® Cyclo was well-tolerated and may slow disease progression, with potential long- term stabilization compared to the natural course of NPC Study 2012 Phase 1 study in NPC patients ages 18 years and older showed Trappsol® Cyclo was well- tolerated with an acceptable safety and tolerability profile Consistent pharmacodynamic effects and safety profile observed in a 48-week Phase 1/2 study in NPC patients aged 2 years and older Potential to treat both the systemic and neurological manifestations of NPC and is well-tolerated with acceptable safety and tolerability profile 1. Molecular Genetics and Metabolism Report: Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo ) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial (2022) 2. Molecular Genetics and Metabolism Report: The Long-term administration of intravenous Trappsol® Cyclo (HPβCD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease Type C1: Results of an international 48-week Phase I/II trial (2023) 9 of 9 (100%) completer patients exhibited stabilized or improved in CGI-I ratings, a clear indicator of efficacy in NPC-1 patients. 8 of 9 (89%) completer patients showed Improvements over disease progression (2.15 points per annum) in the 5D-NPC-SS.

11 Phase 1/2 Study (CTD-TCNPC-201) • Therapeutic benefit may be seen by 48 weeks vs. disease progression • Small cohort (9 patients) limits extensive analysis • Transient variations may mimic disease progression but should lessen in Phase 3 (CTD-TCNPC-301) • 9 completers: 2 at 1500 mg/kg | 4 at 2000 mg/kg | 3 at 2500 mg/kg • 3 excluded from analysis: • 1 with only baseline data • 2 discontinued before Week 48 (non-safety reasons) Data Included Key Outcomes 5D NPCSS primary endpoint for the Phase 3 study Potential benefit may be observed at or before 48 weeks

12 Phase 1/2 Study (CTD-TCNPC-201): Continued • 9 completers: 2 at 1500 mg/kg | 4 at 2000 mg/kg | 3 at 2500 mg/kg • 3 excluded from analysis: • 1 with only baseline data • 2 discontinued before Week 48 (non-safety reasons) Data Included Key Outcomes Individual data suggestive of potential benefit on 5D-NPC-SS & CGI-I • 67% (6/9) completers stabilized or improved on the 5D-NPC-SS • 89% (8/9) completers showed improvement over disease progression (2.15 points/year) on the 5D-NPC-SS • 100% (9/9) completers stabilized or improved in CGI-I ratings, indicating efficacy in NPC-1 patients

13 Phase 1/2 Study (CTD-TCNPC-201): Continued Dosage data suggestive of potential benefit on SARA, an exploratory measure • Multiple domains analyzed: gait, stance, sitting, speech, finger chase (L/R), nose-finger (L/R), fast alt hands (L/R), heel-shin (L/R) • 2500 mg/kg & 2000 mg/kg groups showed stabilized or improved gait, stance, sitting, speech vs. baseline • 2500 mg/kg suggestively improved gait, stance and speech at 48 weeks (Figure A-D) • 2000 mg/kg suggestively improved stance and stabilized sitting, speech at 48 weeks (Figure E-H) • Dose-ordered benefits observed; higher exposures may yield more consistent effects, though sample size is small • SARA domain scores analyzed at a group level for: • 2500 mg/kg | 2000 mg/kg | 1500 mg/kg doses • Patient-level data focused on: • Gait, stance, sitting and speech 1500 mg/kg group excluded from further analysis due to incomplete/missing 48-week data Data Included Key Outcomes

14 Ongoing Long-Term Extension (OLE) Study (CTD-TCNPC-102) Data Included is from an August 2023 Data Cut Key Outcomes from the OLE • To date, 3 patients remain on active treatment • All receive 1500 mg/kg biweekly via in-home infusions • All 5 patients showed slowed disease progression, with some stabilizing or improving • Suggestive evidence of Trappsol® Cyclo 's durability as a chronic medication • Safety and tolerability align with past and ongoing trials; well tolerated Efficacy Data From Ongoing Long-Term Extension (OLE) Study Suggestive evidence of durability of effect

15 Safety From Completed and Ongoing Long-Term Treatment Treatment-Emergent Adverse Events majority mild to moderate in severity, manageable and monitorable and most considered unrelated to Trappsol® Cyclo No evidence of any untoward effects of Trappsol® Cyclo on core organ systems (cardiovascular, respiratory, renal, hepatic, gastrointestinal systems or CNS) Safety and tolerability profile consistent across studies and treatment duration, irrespective of age spectrum and disease severity Hearing loss and infusion reactions (most localized) are adverse events of interest Events of hearing loss resolved in most patients, with hearing returning to baseline levels or improved and stabilized while patients continued on study drug A degree of hearing impairment remained at the last available auditory assessment in a limited number of patients The effect on hearing will continue to be monitored closely in the ongoing studies

16 Ongoing Pivotal Phase 3 Study in Niemann-Pick Disease Type C1 Number of Subjects 104 enrolled: 94 Core Study; 10 Sub Study Current Sites 30+ across 14 countries Duration 96-week trial Dose 2000 mg/kg via IV infusion Substudy (Patients 0-3)2 Requested as part of our adopted PIP to potentially treat as a prophylactic treatment option 96-week LPLV completed June 2026; Pre NDA Meeting completed; NDA submission and Topline data expected 2nd half calendar 2026 1. Substudy is only being conducted ex-US. Patients are not randomized and all patients in the 0-3 cohort receive Trappsol® Cyclo .

17 Trial Design: Core-Study (≥3 Years of Age) – Global Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study Number of Subjects 94 randomized (2:1 to Placebo) Primary Endpoint NPC Composite Severity Score Secondary Endpoints SCAFI, Swallow, Vineland-2 Exploratory Endpoints Inclusive of speech, liver and lung function Baseline Assessment Final Analysis (Week 96) Interim Analysis Completed (Week 48) Screening (2 Weeks) Hydroxypropyl-Beta-Cyclodextrin + SOC vs. Placebo + SOC Administered IV Every 2 Weeks Continuation of HPβCD + SOC until week 192 V1 Week-8 to -5 V2 Week-4 to -1 V3 Week 0 V4 Week 2 V5 Week 4 V9 Week 12 V15 Week 24 V21 Week 36 V27 Week 48 V33 Week 60 V39 Week 72 V45 Week 84 V51 Week 96 V52 Week 98 Study Drug Infusions Following Required Assessments every 2 weeks

18 Trial Design: Sub-Study (Newborn to <3 Years of Age) – Global Open Label Phase Baseline Assessment Final Analysis (Week 96) Screening (2 Weeks) Hydroxypropyl-Beta-Cyclodextrin + SOC Administered IV Every 2 Weeks Continuation of HPβCD + SOC until week 192 V1 Week-8 to -5 V2 Week-4 to -1 V3 Week 0 V4 Week 2 V5 Week 4 V9 Week 12 V15 Week 24 V21 Week 36 V27 Week 48 V33 Week 60 V39 Week 72 V45 Week 84 V51 Week 96 V52 Week 98 Study Drug Infusions Following Required Assessments every 2 weeks Number of Subjects 10 randomized Study Objectives • To evaluate the safety and tolerability • To evaluate the improvement using the CGI-S, CGI-C, CaGI-S, CaGI-C, and CaGI C24 scales • To evaluate the PK

19 Clinical Global Impression–Change (CGI-C) Bar Plot at data cutoff on 14-May-2025 • Graphs shows individual patients (N=10) • 2 patients have withdrawn from the study at week 48 for non-safety related reasons • Trappsol® Cyclo continues to demonstrate stabilization or improvement in the majority of patients and is well-tolerated consistent with previous studies

20 Safety from ongoing Substudy at data cutoff on 14-May-2025 • There were 146 AEs, the reported as mild (69%) moderate (29%), and Severe (2%) • No SAEs were considered by the principal investigators as related to or possibly related to study drug.

21 Trappsol® Cyclo Positioning in the Emerging NPC Treatment Paradigm • NPC landscape evolving from no therapy → multi-drug paradigm • Recent approvals (Zevra, IntraBio) enable combination approaches • Distinct upstream mechanism — removes cholesterol independent of NPC1/NPC2 • Complementary to approved therapies across disease layers • Competes for backbone disease-modifying role • IV only therapy to treat systemic aspects of disease as well as neurological • IV only therapy to that can be delivered at birth (full-term babies) • Positioned for combination standard of care • Opportunity to redefine NPC treatment paradigm

Attribute Trappsol® Cyclo Zevra (Miplyffa) IntraBio (Aqneursa) Mechanism of Action Direct Cholesterol clearance (root cause) lysosomal/ proteostasis enhancement, approved prescribing information states Unknown. neurological function modulation, approved prescribing information states Unknown. Therapeutic Target Systemic + CNS disease modification Primarily neurological progression Symptomatic neurological improvement Role in Treatment Paradigm Potential Backbone/ Foundational therapy Disease-modifying adjunct (with miglustat) Symptomatic monotherapy of add-on Clinical Impact Addresses underlying disease biology Slows progression via cellular pathways Improves function outcomes Patient Population Broad, including early/pediatric Adults and pediatrics patients 2 years of age and older Adults and pediatrics patients weighing ≥ 15 kg Administration IV (biweekly) Oral Oral Combination Potential High (mechanistically complementary) Moderate (already combo) High (symptom layer) 22 Target Product Profile Comparison

23 Investment Summary Phase 3 Clinical trial LPLV June 2026; NDA submission and Topline data expected 2nd half 2026 1. Intelligence, D. (n.d.). Niemann Pick Disease market size, sustainable insights and growth report 2025-2033. DataMIntelligence 2. As of April 30, 2026 Ability to Realize Potential Value Creation Significant Commercial Opportunity ~$30.5M Cash Balance2 ✓Global NPC market expected to reach >$920m by 20331 ✓Recent US approved NPC product pricing is consistent with pricing analogs ranging from $400K to $1.3M ✓Streamlined company focused on bringing Trappsol® Cyclo to market ✓ all-in-one Endoscopic Carpal Tunnel Release system, approved by FDA December 2024 ✓Sufficient capital to fund the company through multiple potentially value creating milestones

NYSE: RFL Thank You! 24

GRAPHIC

Filename: ea029744201_ex99-1img1.jpg · Sequence: 3

Binary file (114096 bytes)

Download ea029744201_ex99-1img1.jpg

GRAPHIC

Filename: ea029744201_ex99-1img2.jpg · Sequence: 4

Binary file (882961 bytes)

Download ea029744201_ex99-1img2.jpg

GRAPHIC

Filename: ea029744201_ex99-1img3.jpg · Sequence: 5

Binary file (238096 bytes)

Download ea029744201_ex99-1img3.jpg

GRAPHIC

Filename: ea029744201_ex99-1img4.jpg · Sequence: 6

Binary file (399685 bytes)

Download ea029744201_ex99-1img4.jpg

GRAPHIC

Filename: ea029744201_ex99-1img5.jpg · Sequence: 7

Binary file (269372 bytes)

Download ea029744201_ex99-1img5.jpg

GRAPHIC

Filename: ea029744201_ex99-1img6.jpg · Sequence: 8

Binary file (388618 bytes)

Download ea029744201_ex99-1img6.jpg

GRAPHIC

Filename: ea029744201_ex99-1img7.jpg · Sequence: 9

Binary file (241278 bytes)

Download ea029744201_ex99-1img7.jpg

GRAPHIC

Filename: ea029744201_ex99-1img8.jpg · Sequence: 10

Binary file (469623 bytes)

Download ea029744201_ex99-1img8.jpg

GRAPHIC

Filename: ea029744201_ex99-1img9.jpg · Sequence: 11

Binary file (559363 bytes)

Download ea029744201_ex99-1img9.jpg

GRAPHIC

Filename: ea029744201_ex99-1img10.jpg · Sequence: 12

Binary file (444626 bytes)

Download ea029744201_ex99-1img10.jpg

GRAPHIC

Filename: ea029744201_ex99-1img11.jpg · Sequence: 13

Binary file (308861 bytes)

Download ea029744201_ex99-1img11.jpg

GRAPHIC

Filename: ea029744201_ex99-1img12.jpg · Sequence: 14

Binary file (368451 bytes)

Download ea029744201_ex99-1img12.jpg

GRAPHIC

Filename: ea029744201_ex99-1img13.jpg · Sequence: 15

Binary file (471321 bytes)

Download ea029744201_ex99-1img13.jpg

GRAPHIC

Filename: ea029744201_ex99-1img14.jpg · Sequence: 16

Binary file (335780 bytes)

Download ea029744201_ex99-1img14.jpg

GRAPHIC

Filename: ea029744201_ex99-1img15.jpg · Sequence: 17

Binary file (473817 bytes)

Download ea029744201_ex99-1img15.jpg

GRAPHIC

Filename: ea029744201_ex99-1img16.jpg · Sequence: 18

Binary file (326384 bytes)

Download ea029744201_ex99-1img16.jpg

GRAPHIC

Filename: ea029744201_ex99-1img17.jpg · Sequence: 19

Binary file (402424 bytes)

Download ea029744201_ex99-1img17.jpg

GRAPHIC

Filename: ea029744201_ex99-1img18.jpg · Sequence: 20

Binary file (344131 bytes)

Download ea029744201_ex99-1img18.jpg

GRAPHIC

Filename: ea029744201_ex99-1img19.jpg · Sequence: 21

Binary file (286863 bytes)

Download ea029744201_ex99-1img19.jpg

GRAPHIC

Filename: ea029744201_ex99-1img20.jpg · Sequence: 22

Binary file (263985 bytes)

Download ea029744201_ex99-1img20.jpg

GRAPHIC

Filename: ea029744201_ex99-1img21.jpg · Sequence: 23

Binary file (431724 bytes)

Download ea029744201_ex99-1img21.jpg

GRAPHIC

Filename: ea029744201_ex99-1img22.jpg · Sequence: 24

Binary file (401006 bytes)

Download ea029744201_ex99-1img22.jpg

GRAPHIC

Filename: ea029744201_ex99-1img23.jpg · Sequence: 25

Binary file (342124 bytes)

Download ea029744201_ex99-1img23.jpg

GRAPHIC

Filename: ea029744201_ex99-1img24.jpg · Sequence: 26

Binary file (112426 bytes)

Download ea029744201_ex99-1img24.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 31

v3.26.1

Cover

Jul. 08, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 08, 2026

Entity File Number

1-38411

Entity Registrant Name

RAFAEL

HOLDINGS, INC.

Entity Central Index Key

0001713863

Entity Tax Identification Number

82-2296593

Entity Incorporation, State or Country Code

Entity Address, Address Line One

520

Broad Street

Entity Address, City or Town

Newark

Entity Address, State or Province

Entity Address, Postal Zip Code

07102

City Area Code

212

Local Phone Number

658-1450

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Class

B common stock, par value $0.01 per share

Trading Symbol

RFL

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration